Last reviewed · How we verify
OST
OST is an osteoclast inhibitor.
OST is an osteoclast inhibitor. Used for Treatment of osteoporosis in postmenopausal women and men, Treatment of glucocorticoid-induced osteoporosis.
At a glance
| Generic name | OST |
|---|---|
| Sponsor | Pharmbio Korea Co., Ltd. |
| Drug class | Bisphosphonate |
| Target | Farnesyl pyrophosphate synthase |
| Modality | Small molecule |
| Therapeutic area | Osteoporosis |
| Phase | FDA-approved |
Mechanism of action
OST works by inhibiting the activity of osteoclasts, which are cells responsible for bone resorption. This leads to an increase in bone density and a decrease in the risk of fractures. OST is used to treat osteoporosis and other bone-related disorders.
Approved indications
- Treatment of osteoporosis in postmenopausal women and men
- Treatment of glucocorticoid-induced osteoporosis
Common side effects
- Esophageal irritation
- Dental problems
- Musculoskeletal pain
- Nausea
- Abdominal pain
Key clinical trials
- Autophagy and Pathological Aging (NA)
- Female Osteoporosis
- Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) (NA)
- Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) (NA)
- Data Coaching Process to Address Staff Physical Activity Promoting Behavior and Child Physical Activity (NA)
- Integrated Treatment of Hepatitis C Virus Infection (NA)
- Project Vuselela Feasibility (NA)
- Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |